Cargando…

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

Detalles Bibliográficos
Autores principales:	Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374076/ https://www.ncbi.nlm.nih.gov/pubmed/25783754 http://dx.doi.org/10.1007/s13300-015-0104-4

Ejemplares similares

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
por: Schweizer, Anja, et al.
Publicado: (2013)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management
por: Dejager, Sylvie, et al.
Publicado: (2011)

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
por: Schweizer, Anja, et al.
Publicado: (2013)

Obesity-Related Glomerulopathy and Single-Nephron GFR
por: Denic, Aleksandar, et al.
Publicado: (2020)

Automated estimated GFR reporting: A new tool to promote safer prescribing in patients with chronic kidney disease?
por: Harris, KPG, et al.
Publicado: (2007)

Age‐adapted eGFR thresholds underestimate the risks beyond kidney failure associated with CKD in older populations
por: Lees, Jennifer S., et al.
Publicado: (2022)

Penkid: A Novel Biomarker of Reduced GFR in Sepsis
por: Moledina, Dennis G.
Publicado: (2018)

Estimating GFR in the Elderly—New Approaches to an Old Problem
por: Pavkov, Meda E., et al.
Publicado: (2019)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
por: Evans, Marc, et al.
Publicado: (2016)

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
por: Shannon, Richard P.
Publicado: (2013)

“Any fool can make a rule and any fool will mind it”
por: Wells, Athol U.
Publicado: (2016)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

GFR Estimation in Potential Living Kidney Donors: Race- and Nonrace-based Equations and Measured GFR
por: Goodson, David Alex, et al.
Publicado: (2022)

The Error of Estimated GFR in Type 2 Diabetes Mellitus
por: Luis-Lima, Sergio, et al.
Publicado: (2019)

COVID-19 and diabetes: Can DPP4 inhibition play a role?
por: Iacobellis, Gianluca
Publicado: (2020)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

Mesotherapy in Management of Hairloss — Is it of Any Use?
por: Mysore, Venkataram
Publicado: (2010)

Child Neglect by Any Other Name
por: Roach, E. Steve
Publicado: (2020)

Reimbursement Policies for Diabetes Prevention Program (DPP): Implications for Racial and Ethnic Health Disparities
por: Formagini, Taynara, et al.
Publicado: (2021)

Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study
por: Kammer, Michael, et al.
Publicado: (2023)

Crystalloid or colloid for resuscitation. Are we any the wiser?
por: Webb, Andrew R
Publicado: (1999)

Commentary: A rose by any other name
por: Wei, Lawrence M., et al.
Publicado: (2021)

Monkeypox and Male Fertility: Is There Any Looming Danger?
por: du Plessis, Stefan S, et al.
Publicado: (2022)

Open Chromatin State of Dpp4 With Glucocorticoid Treatment—Setting up Shop for Metasteroid Diabetes?
por: Morrow, Nadya M, et al.
Publicado: (2021)

Assessment of kidney function: clinical indications for measured GFR
por: Ebert, Natalie, et al.
Publicado: (2021)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
por: Darsalia, Vladimer, et al.
Publicado: (2018)

Impact of Pregnancy on GFR Decline and Kidney Histology in Kidney Transplant Recipients
por: Kattah, Andrea G., et al.
Publicado: (2021)

Neuroprotective properties of DPP‐4i: A therapeutic target for dementia prevention in elderly diabetic patients?
por: Umemura, Toshitaka, et al.
Publicado: (2023)

Pathogenesis and biomarkers for necrotizing enterocolitis: Getting any closer?
por: Nguyen, Duc Ninh, et al.
Publicado: (2019)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Podocyturia: Is there any clinical utility?
por: Yadav, I., et al.
Publicado: (2011)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Improved estimation of glomerular filtration rate (GFR) by comparison of eGFR(cystatin C) and eGFR(creatinine)
por: Grubb, Anders, et al.
Publicado: (2012)

Commentary: Do you have any doctors in your family?
por: Mays, Jarvis C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3tvc3r0uoun9pp76sgo2ek92g1